stella
beta
Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer — Stella
Recruiting
Back to Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) trials
Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations
(2 sites)
China
Hunna Cancer Hospital, Clinical Trails Center, Changsha, Hunan
Hunan Cancer hospital, Changsha, Hunan
View full record on ClinicalTrials.gov